Dupuis Derma, Fritz Kasinda, Ike Emeka, Arogundade Oyinkansola, Adewara Enoch O, Monday Esther O, Ayinde Bolaji O
Department of Research, All Saints University, School of Medicine, Roseau, DMA.
Faculty of Medicine, All Saints University, School of Medicine, Roseau, DMA.
Cureus. 2022 Sep 1;14(9):e28680. doi: 10.7759/cureus.28680. eCollection 2022 Sep.
The levels of infectivity and mortality that ensued due to the coronavirus disease 2019 (COVID-19) pandemic caused an apparent global outcry. The health system, burdened by increasing deaths and hospitalizations, sought more effective treatment. This necessitated scientists and researchers to utilize existing drugs such as baricitinib, which has proved itself as anti-inflammatory and immunomodulatory. A qualitative systematic review was conducted using databases such as Google Scholar, Science Direct, PubMed, and BioMed Central to locate relevant articles published from 2019 onward on the effectiveness of baricitinib. After evaluation of the full-text articles, 16 were selected for review. Overall, baricitinib was seen as beneficial in decreasing respiratory failure and the use of mechanical ventilation, also preventing deterioration of COVID-19 symptoms. When used as a single agent or combined with other drugs, baricitinib improves the peripheral capillary oxygen saturation (SpO2)/fraction of inspired oxygen (FiO2) ratio. The drug does not introduce any major side effects, but a mild increase in liver enzymes has been observed. Baricitinib proves to be a safe and effective treatment for COVID-19. Administered as monotherapy or in conjunction with other drugs, baricitinib provides tremendous clinical benefit to infected patients and shows good potential in terms of efficacy for future COVID-19 regimens.
2019年冠状病毒病（COVID-19）大流行所导致的感染率和死亡率引发了全球范围内的明显抗议。卫生系统因死亡人数和住院人数不断增加而不堪重负，于是寻求更有效的治疗方法。这使得科学家和研究人员开始使用诸如巴瑞替尼等现有药物，该药物已证明具有抗炎和免疫调节作用。我们利用谷歌学术、科学Direct、PubMed和生物医学中心等数据库进行了一项定性系统评价，以查找2019年以来发表的有关巴瑞替尼有效性的相关文章。在对全文进行评估后，选择了16篇进行综述。总体而言，巴瑞替尼被认为有助于降低呼吸衰竭和机械通气的使用率，还能防止COVID-19症状恶化。当作为单一药物使用或与其他药物联合使用时，巴瑞替尼可提高外周毛细血管血氧饱和度（SpO2）/吸入氧分数（FiO2）比值。该药物不会引发任何严重副作用，但观察到肝酶有轻微升高。巴瑞替尼被证明是一种治疗COVID-19的安全有效的药物。作为单一疗法或与其他药物联合使用时，巴瑞替尼为感染患者带来了巨大的临床益处，并且在未来COVID-19治疗方案的疗效方面显示出良好的潜力。
